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Abstract
Background: Non-typable Haemophilus influenzae (NT-Hi) infection is frequently associated with acute otitis media
(AOM) treatment failure, recurrence or chronic otitis media. Persistence of otopathogens in a biofilm-structured
community was implicated in these situations. Here, we compared biofilm production by H. influenzae strains
obtained by culture of middle ear fluid (MEF) from children with AOM treatment failure and by strains isolated
from nasopharyngeal (NP) samples from healthy children or those with AOM (first episode or recurrence). We
aimed to evaluate an association of clinical signs and in vitro biofilm formation and establish risk factors of
carrying a biofilm-producing strain.
Methods: We used a modification of the microtiter plate assay with crystal violet staining to compare biofilm
production by 216 H. influenzae strains: 41 in MEF from children with AOM treatment failure (group MEF), 43 in
NP samples from healthy children (NP group 1), 88 in NP samples from children with a first AOM episode (NP
group 2, n = 43) or recurrent (NP group 3, n = 45) and 44 in NP samples from children with AOM associated with
conjunctivitis (NP group 4).
Results: At all, 106/216 (49%) H. influenzae strains produced biofilm as did 26/43 (60.5%) in NP samples from
healthy children. Biofilm production in MEF samples and NP samples did not significantly differ (40.5% vs 60.5%,
55.8%, 56.8% and 31.1% for NP groups 1, 2, 3 and 4, respectively). On multivariate analysis, only presence of
conjunctivitis was significantly associated with low biofilm production (OR = 0.3, CI [0.16-0.60], p = 0.001). The
ampicillin resistance of H. influenzae produced by penicillin-binding protein modification was significantly
associated with low biofilm production (p = 0.029).
Conclusion: We found no association of biofilm production and AOM treatment failure or recurrence. Biofilm
production was low from H. influenzae strains associated with conjunctivitis-otitis syndrome and from strains with
modified penicillin-binding protein.
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Background
Non-typable H. influenzae (NT-Hi) is a commensal bacter-
ium of the human respiratory tract and can be responsible
for non-invasive diseases such as acute otitis media (AOM)
and sinusitis. With the expanded use of 7-valent pneumo-
coccal vaccination, Streptococcus pneumoniae and NT-Hi
are the two most common bacteria implicated in AOM
[1,2]. Couloigner et al. recently reported that after the
7-valent Pneumococcal Conjugate Vaccine implementation
in France, S. pneumoniae and NT-Hi infection were equally
frequent among children with AOM treatment failure.
Indeed, the serotype 19A, not included in the vaccine, was
the main S. pneumoniae serotype reported and represented
84.5% of all serotypes detected [3].
NT-Hi is frequently associated with AOM treatment
failure, recurrence and otitis media effusion [4,5]. Faden
et al. demonstrated that nasopharyngeal (NP) colonization
with NT-Hi is an important risk factor for AOM [6].
AOM is more likely to develop in children with than with-
out frequent NP colonization with NT-Hi [6,7]. Kaur et al.
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used multi-locus sequence typing to compare strains iso-
lated from NP and middle ear fluid (MEF) in 34 children
during an AOM episode. They found the same sequence
type of NT-Hi in 31 (84%) children, which highlights the
close relationship between strains isolated from both sites
[8]. Furthermore, because of the pain caused by tympano-
centesis, bacteriological samples of MEF are generally not
recommended in most guidelines for AOM followed by
paediatricians or general practitioners, except in case of
treatment failure [8].
Several studies have shown that NT-Hi forms biofilms
in vivo and in vitro [9,10]. A biofilm is a community of
microorganisms adhering to a surface and enclosed in a
self-produced extracellular matrix (ECM). This structure
protects against external aggression such as the host im-
mune system and antibiotics treatment [11]. Biofilm for-
mation was originally suggested to explain the failure to
culture NT-Hi from middle-ear effusions, resistance to
antibiotics and pathogenic behavior. Bacterial biofilms
are mainly present in chronic infections, such as chronic
pulmonary infections caused by Pseudomonas aerugi-
nosa in cystic fibrosis patients or in medical-device–
related infections mainly due to Staphylococcus aureus
or Staphylococcus epidermidis [12,13]. Persistence of
NT-Hi in a biofilm-structured community was impli-
cated in the pathogenesis of chronic and recurrent otitis
media [10,11]. The mechanism seems to be an inefficient
clearance of bacteria from the middle ear [14]. However,
this hypothesis remains controversial [15].
Here, we aimed to determine whether biofilm pro-
duction is increased in bacterial strains from children
with AOM treatment failure. We compared the in vitro
biofilm-forming ability of H. influenzae strains in MEF
from children with AOM treatment failure and in NP
samples from children with a first episode or recurrent
AOM with or without conjunctivitis or in NP microbiota
from healthy children. In addition, we evaluated a possible
association of clinical signs and in vitro biofilm formation




After the implementation of PCV7 in France, we con-
ducted two studies in parallel during the same period
(May 2007 to April 2009). In the first study, ear, nose
and throat specialists obtained MEF samples from
children with AOM treatment failure [3]. This study
enrolled 143 children (mean age 16.9 ± 9 months). The
second study examined the NP carriage of S. pneumo-
niae and H. influenzae in healthy children and children
with AOM [3].
Treatment failure was defined as otorrhea or bulging of
the tympanic membrane, together with fever and otalgia
(or its equivalent: irritable or ill-tempered child), despite
at least 48 hr of antibiotics, or recurring < 4 days after the
end of antimicrobial treatment. Recurrence was defined
by the reappearance of AOM signs and symptoms 4
to 30 days after the end of antimicrobial treatment [16].
The definitions of recurrence and failures applied to all
patients of all groups.
Establishment of patient groups
In the first study of 143 children with AOM treatment
failure or recurrence, H. influenzae was found in MEF
cultures from 45 children, which constituted the “MEF
group” in this study.
Among the children enrolled in the NP surveillance
study, 98 healthy children and 481 children with AOM
were carrying H. influenzae. Because tympanocentesis
is not recommended for first-line treatment of AOM,
we used NP samples and stringent criteria for the diag-
nosis of otitis. We defined 4 NP groups: 1) NP group 1,
H. influenzae strains in NP samples from 98 healthy
children; 2) NP group 2, H. influenzae strains in NP
samples from 82 children with a first AOM without
conjunctivitis; 3) NP group 3, H. influenzae strains in
NP samples from 57 children with recurrent AOM with-
out conjunctivitis; and 4) NP group 4, H. influenzae
strains in NP samples from 342 children with first or
recurrent AOM associated with conjunctivitis.
From each of these 4 groups, we randomly selected
representative samples of 45 children (one strain per
child). For NP group 4 (first or recurrent AOM), we
did not have information about history of otitis for 23
children; 13 had previous otitis, and AOM was the first
episode for 9 children. Therefore, because of the low
number of children in each subgroup (first or recurrent
otitis), this group cannot be divided. Co-carriage of
H. influenzae and S. pneumoniae in NP samples was
considered (Figure 1).
Ethics approval
The two studies used standardized protocols and common
inclusion criteria for AOM and enrolled children of the
same age. Furthermore, they involved mostly the same in-
vestigators and centralized microbiology laboratories. The
protocols were approved by the Saint Germain en Laye
Hospital Ethics Committee. Written informed consent
was obtained from parents or legal representatives.
B) Methods
Samples
Deep NP samples were taken transnasally with use of
a flexible, sterile, soft rayon swab tip. After sampling,
swabs were immediately inoculated in transport medium
(Copan Venturi Transystem, Brescia, Italy), stored at
ambient temperature and sent most often during the day
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and no more than 48 hr later to the “Centre National de
Référence des Pneumocoques” (Hôpital Européen Georges
Pompidou, Paris) and to the Robert Debré Hospital
Bacteriological Laboratory (Paris). Bacterial strains were
frozen in each laboratory at -80°C in brain heart infu-
sion broth (BHI) with 10% glycerol (Mérieux, Marcy
l'Etoile, France). MEF was obtained by tympanocentesis
and/or by sampling spontaneous discharge according to
the recommended clinical practice guidelines. After
collection, MEF specimens were transported to the
centralized microbiology laboratories.
Culture
Swabs and MEF were plated within 24 hr onto chocolate
and blood agar (Biomérieux, La Balme Les Grottes,
France) and incubated at 37°C for 48 hr with 5% CO2.
Both S. pneumoniae and H. influenzae were identified.
Isolates of H. influenzae were identified by colony morph-
ology and conventional methods of determination. Then,
isolates underwent capsular serotyping by the slide ag-
glutination method with specific antisera (Phadebact,
Boule Diagnostic, Huddinge, Sweden). The production
of ß-lactamase was assessed by a chromogenic cephalo-
sporin test (Nitrocefin, Cefinase; Biomerieux, Marcy
l’Etoile, France). Ampicillin-resistant, non-β-lactamase–
producing H. influenzae (BLNAR) was identified on a
30-μg Cefalotin disk (<17-mm inhibition zone diameter)
on Haemophilus test medium (HTM) plates (Becton
Dickinson, Le Pont-De-Claix, France) according to the
2013 statement of the “Comité de l'Antibiogramme de
la Societé Francaise de Microbiologie” [17].
Microtiter biofilm formation assay
The biofilm formation by H. influenzae isolates was eval-
uated by a modified microtiter plate assay with crystal
violet (CV) staining [18]. This assay was based on the
ability of bacteria to adhere to solid polystyrene surfaces
by producing a biofilm. Indeed, as a cationic dye, CV
will bind to the predominant matrix components (e.g.,
exopolysaccharides), specifically uronic acids or ketal-
linked pyruvate [19]. H. influenzae strains were sub-
cultured on chocolate agar (Biomérieux, La Balme Les
Grottes, France) and incubated at 37°C for 24 hr with
5% CO2. Identification of all strains was confirmed by
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Sp : Streptococcus pneumoniae
NP   : Nasopharyngeal samples
MEF : Middle ear fluid
AOM: acute otitis media
Figure 1 Composition of the groups of children and isolated bacteria from middle ear fluid (MEF) or nasopharyngeal samples (NP).
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matrix-assisted laser desorption ionization-time of flight
mass spectrometry (MALDI-TOF MS, Bruker Daltonics,
Germany) with the database provided by the Haemophi-
lus National Reference Center [20].
Then H. influenzae isolates were grown overnight in BHI
broth (Becton Dickinson, Le Pont-De-Claix, France) sup-
plemented with 15 mg/L nicotinamide adenine dinucleo-
tide and hemin (HTM supplemented, Oxoid, Basingstoke
Hampshire, UK). The suspension was washed with sterile
phosphate buffered saline and diluted 1:200 in fresh
supplemented BHI broth. In total, 200 μlH. influenzae
suspension was inoculated into wells of a polystyrene
flat-bottomed 96-well microtiter plates (Nunc, Kracker
Scientific, Inc, Albany, New York), which were incu-
bated at 37°C for 24 hr aerobically with 5% CO2. The
growth of H. influenzae was assessed by measuring op-
tical density absorbance at 595 nm (OD595nm). Culture
media including unattached bacteria was decanted from
wells, and the remaining planktonic H. influenzae cells
were removed by rinsing with distilled water. The wells
were air-dried and adhered bacteria were stained
with 0.5% (w/v) CV solution (Sigma-aldrich, USA) for
15 min. After rinsing with distilled water, bound CV
was released from H. influenzae cells by a 20% acetone–
80% ethanol solution. Thus, biofilm formation could be
measured on both bottoms and sides of wells. Biofilm
formation was quantified by measuring the absorbance
at OD595nm.
A strain of S. aureus producing biofilm and a strain of
Lactococcus lactis non-producing biofilm were included
in each experiment as controls. These strains were
kindly provided by the Streptococci national reference
center (Cochin Hospital, Paris). The assays were per-
formed in triplicate. For each assay, the BHI broth alone
was tested to calculate the biofilm formation index
(BFI).
Determination of the cut-off value
The BFI was determined by use of three different formu-
las. With the first formula [21], BFI = AB-CW, where AB
represents the optical density at 595 nm (OD595nm) of
a well containing stained attached bacteria and CW,
the OD595nm of the stained control wells containing
bacteria-free medium only, here supplemented with
BHI. With the second formula [22], BFI = AB/CW. With
the third formula [23], BFI = (AB-CW)/G, where G is
the OD595nm of bacterial growth control. The assays
were performed in duplicate. Finally, results were
studied by terciles to classify biofilm production semi-
quantitatively in three categories for each formula:
strong production (S), moderate production (M) and
absence of production (N) according to the cut-off
values proposed by Naves et al. [24]. Because Naves
et al. [24] showed that biofilm formation was strongly
modulated by culture conditions, environmental factors
and methodology, we combined the three BFI formulas
to overcome above factors.
Statistical analysis
Double data entry was performed with use of the soft-
ware 4D v 12. Univariate analysis and multivariate logis-
tic regression models and estimation of odds ratios
(ORs) and 95% confidence intervals [CI] involved use of
Stata SE v11.2 (Stata Corp., College Station, TX, USA).
The Pearson chi-square test was used to compare
groups. Potential risk factors were identified by univari-
ate analysis (p <0.25) and applied in multivariate logistic
regression models. Factors considered were history of
AOM, conjunctivitis, associated carriage of S. pneumo-
niae and BLNAR strains. P < 0.05 was considered statis-
tically significant.
Results
Among the 225 selected strains, 9 were not found in the
collection of frozen samples and therefore could not be
included. So, we analyzed the remaining 216 strains.
All strains were identified by MALDI-TOF MS. When
the result was not sufficiently discriminative between
H. influenzae and H. haemolyticus, the identification of
H. influenzae was confirmed by sequencing sodAint, recA
and fucK genes [25].
Among the 171 isolates in NP samples, only 2 (1.1%)
were serotype b H. influenzae. All of the 45 strains iso-
lated in MEF were non-typable strains.
Among the 216 strains, 37 produced β-lactamase
(17.1%), 32 were BLNAR (14.8%) and 7 showed both
mechanisms of resistance (3.2%).
1) Comparison of the three methods to calculate BFI
Among the 216 studied strains, 162 (75%) were clas-
sified in the same category of biofilm production
(strong, moderate or absence) by the three formulas.
For 54 strains, results were discordant. However, in
each case, results were concordant with two of the
three formulas. Therefore, these 54 strains were
classified by agreement in two of the three formulas.
Finally, 47/216 (21.7%) strains of H. influenzae were
classified as strong producers of biofilm and 59/216
(27.3%) as moderate producers; 110/216 (51%) did
not produce biofilm. In total, 106 (49%) strains pro-
duced biofilm.
2) Relationship between pathology and biofilm production
To describe the effect of biofilm production by
pathology, results were combined for two categories:
strains producing biofilm (moderate or strong produc-
tion) and strains not producing biofilm (negative).
In the control group of healthy children (NP group 1),
60.5%H. influenzae strains produced biofilm (Table 1).
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Table 1 Association of pathologic group and biofilm production by isolated H. influenzae strains
Groups Level of biofilm production Comparison between groups *p value OR [95% CI]
Negative Moderate Strong Moderate + Strong Reference vs Group 1 Reference vs Group 2 Reference vs Group 3 Reference vs Group 4
Group MEF** n = 41 24 (58.5%) 8 (19.5%) 9 (22%) 17 (40.5%) 0.083 0.19 0.16 0.32
AOM treatment failure 2.16 [0.90;5.16] 1.78 [0.75;4.24] 1.86 [0.79;4.40] 0.64 [0.26;1.55]
NP group 1*** n = 43 17 (39.5%) 11 (25.6%) 15 (34.9%) 26 (60.5%) 0.66 0.73 0.006
Control (healthy children) 1.21 [0.51;2.86] 1.16 [0.49;2.73] 3.39 [1.41;8.15]
NP group 2*** n = 43 19 (44.2%) 18 (41.9%) 6 (13.9%) 24 (55.8%) 0.93 0.02
First AOM without conjunctivitis 0.96 [0.41;2.24] 2.8 [1.17;6.69]
NP group 3*** n = 45 19 (43.2%) 13 (29.5%) 12 (27.3%) 25 (56.8%) 0.015
Recurrent AOM without conjunctivitis 0.34 [0.14;0.82]
NP group 4*** n = 44 31 (68.9%) 9 (20%) 5 (11.1%) 14 (31.1.5%)
AOM with conjunctivitis
OR, odds ratio; 95% CI, 95% confidence interval.
*Risk for carrying (moderate + strong) an H. influenzae strain producing biofilm.
**Strains isolated from MEF.



















Considering the influence of biofilm production on
AOM recurrence, we found no difference between
strains in NP during a first AOM episode or during
recurrent AOM in the absence of conjunctivitis (NP
group 2 vs NP group 3, 55.8% vs 56.8%, respectively,
p = 0.93, OR = 0.96 [95% CI, 0.41; 2.24]) (Table 1).
We found no significant difference in biofilm pro-
duction from strains in MEF (children with AOM
treatment failure) and strains in NP samples (NP
groups 1, 2, 3 and 4): 40.5% vs 60.5% (p = 0.083, OR =
2.16 [0.90;5.16]), 55.8% (p = 0.19, 1.78 [0.75;4.24]),
56.8% (p = 0.16, 1.86 [0.79;4.40]) and 31.1% (p = 0.32,
0.64 [0.26;1.55]), respectively.
However, H. influenzae strains in NP samples from
children with both AOM and conjunctivitis (NP
group 4) produced significantly less biofilm (68.9%
non-producer) than strains from NP groups 1, 2 and
3 (p = 0.006 and OR = 3.39 [1.41;8.15], p = 0.0; 2.8
[1.17;6.69], p = 0.015; and 0.34 [0.14;0.82], respect-
ively). Biofilm production did not significantly differ
between strains in MEF and in NP samples from
children with AOM and conjunctivitis. For most of
the comparisons, the number of patients was too
small and the differences between groups too low to
demonstrate significant differences.
Finally, biofilm production did not significantly differ
between NP group 1 strains (healthy children,
60.5%) and those from children with a first or recur-
rent AOM without conjunctivitis, NP groups 2
(55.8%, p = 0.66, OR = 1.21 [0.51; 2.86]) and 3 (56.8%,
p = 0.73, 1.16 [0.49; 2.73).
3) Risk factors for carriage of H. influenzae producing
biofilm
We examined associations between risk factors for
H. influenzae carriage and biofilm production by
univariate analysis. Age less or greater than 12 months
old as well as type of daycare (daycare center, home or
nurse) were not associated with carriage of a strain
producing biofilm (p = 0.36 and 0.61, respectively)
(Table 2).
H. influenzae was often found with S. pneumoniae
(44.9% of cases). Although H. influenzae produced
more biofilm with than without S. pneumoniae co-
habitation (OR = 1.6 CI [0.94; 2.78]), the difference
was not significant (55.7% with vs 43.7% without co-
habitation, p = 0.08). Antibiotic treatment, amoxicil-
lin or third-generation cephalosporin taken in the
previous 3 months was not a risk factor for carrying
an H. influenzae strain producing biofilm, p=0.71
(Table 2).
Two factors were significantly associated with low bio-
film production. The first was ampicillin resistance of
H. influenzae by modification of the penicillin-binding
protein (PBP) (BLNAR strains) (31.2% producing
biofilm by ampicillin-resistant strains vs 52.2% by
ampicillin-susceptible strains, p = 0.029; OR = 2.4 CI
[1.08; 5.35]) (Table 2). The resistance to ampicillin
mediated by β-lactamase did not affect biofilm pro-
duction. The second risk factor associated with de-
creased biofilm production was the presence of
conjunctivitis-otitis syndrome. Indeed, strains causing
otitis and conjunctivitis produced significantly less
biofilm than those from children with otitis without
conjunctivitis: 27.8% vs 55.6%, p <0.001 (OR = 3.3, CI
[1.66; 6.38]).
4) Multivariate analysis
We examined predictors of low biofilm production
by H. influenzae strains by multivariate analysis of
past history of AOM, presence of conjunctivitis,
co-colonization with S. pneumoniae and PBP
modification. Only presence of conjunctivitis was
significantly associated with low biofilm production
(p = 0.001, OR = 0.3, CI [0.16-0.60]). The OR was
not adjusted.
Discussion
In this study, we examined whether H. influenzae strains
in MEF from children with AOM were high biofilm
producers, causing AOM treatment failure. We found
conjunctivitis-otitis syndrome significantly associated with
low biofilm production by H. influenzae strains (27.8%
production with the syndrome vs 55.6% without). This
association was not previously described. In the absence
of conjunctivitis, biofilm production did not significantly
differ between strains from children with a first, cured
AOM and those with recurrent AOM.
One limitation of the study is the small number of
patients in each group which does not allow for deter-
mining a significant difference in biofilm production by
H. influenzae between strains from healthy controls and
the MEF group (children with AOM treatment failure).
A second limitation is to compare strains from the
MEF and NP samples. Some argue that strains in NP
samples are not responsible for AOM. In a prospective
study, Bingen et al. showed by pulsed-field electrophor-
esis that in conjunctivitis-otitis syndrome, H. influenzae
strains from MEF and conjunctivitis were identical for
the same child [26]. These data are reinforced by the fact
that NT-Hi strains were not clonal and constituted a
considerably diverse population. Van Dongen et al. [27],
in a systematic review of the literature on the concord-
ance between strains isolated from nasopharyngeal and
MEF samples, found that H. influenzae strains were con-
cordant in 80% of the cases.
AOM is the most common bacterial infection in
children with H. influenzae and S. pneumoniae as the
major causative agents. H. influenzae is often found in
samples from children with recurrent AOM or AOM
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treatment failure [4]. A recent hypothesis was the ability
of H. influenzae to produce biofilm and thus escape the
antimicrobial treatment [11]. Bacterial growth in a self-
produced ECM, preventing the action of antibiotics
and an efficient host immune system, can explain the
chronic nature of various infections. However, this hy-
pothesis is still controversial [15]. Recently, Swords et al.
[28] discounted the relevance of NT-Hi biofilms in
disease. Langereis et al. [29] suggested that NT-Hi can
lie in biofilm during both colonization and infection.
The definition of a biofilm is still being discussed.
Toretta et al. [30] reported greater biofilm production
from NT-Hi from children with AOM than from healthy
children. However, this study included only 12 AOM
strains and only one healthy control strain.
We found significantly low biofilm production in
strains with than without modified PBP (OR = 2.4 (CI
[1.08; 5.35]). One hypothesis for this phenomenon is that
resistance to amoxicillin and amoxicillin/clavulanic acid
may promote the planktonic state. As well, biofilm pro-
duction could be considered a real mechanism of resist-
ance, and ß-lactamase production could obviate any
resistance mechanism. These data need to be confirmed
and explored in further studies.
The ECM secreted by H. influenzae is composed of
lipo-oligosaccharides, proteases and adhesins but not a
Table 2 Risk factors for carriage of H. influenzae associated with biofilm production
No. of strains (%) Biofilm non-producer* (n = 110) Biofilm producer** (n = 106) P value OR
Age: n =216
< 12 months 79 (36.6%) 37 (46.8%) 42 (53.2%) 0.361
> 12 months 137 (63.4%) 73 (53.3%) 64 (46.72%)
Types of daycare: n = 216
Daycare center 117 (54.2%) 61 (52.1%) 56 (47.9%) 0.616
Home 49 (22.7%) 22 (44.9%) 27 (55.1%)
Nurse 50 (23.1%) 27 (54%) 23 (46%)
Association with Streptococcus pneumoniae: n = 216
Yes 97 (44.9%) 43 (44.3%) 54 (55.7%) 0.08
No 119 (55.1%) 67 ( 56.3%) 52 (43.7%)
β-lactamase production: n = 216
Yes 37 (17.1%) 21 (56.80%) 16 (43.20%) 0.436
No 179 (82.9%) 89 (49.72%) 90 (50.28%)
Penicillin-binding protein modification: resistance to amoxicillin: n =216
Yes 32 (14.8%) 22 (68.75%) 10 (31.25%) 0.029 2.4 [1.08;5.35]
No 184 (85.2%) 88 (47.83%) 96 (52.17%)
History of AOM: n =172
Yes 104 (60.5%) 54 (51.9%) 50 (48.1%) 0.168
No 68 (39.5%) 28 (41.2%) 40 (58.8%)
Associated conjunctivitis: n = 214
Yes 54 (25.2%) 39 (72.2%) 15 (27.8%) <0.001 3.3 [1.66;6.38]
No 160 (74.8%) 71 (44.4%) 89 (55.6%)
Previous antimicrobial therapy (<3 months): n = 210
None 91 (43.3%) 43 (47.2%) 48 (52.8%) 0.716
Amoxicillin 70 (33.3%) 37 (52.9%) 33 (47.1%)
3GC*** 49 (23.4%) 26 (53.1%) 23 (46.9%)
Pneumococcal vaccination: n = 216
Yes 211 (97.7%) 106 (50.2%) 105 (49.8%) 0.188
No 5 (2.3%) 4 (80.0%) 1 (20.0%)
*No. of strains not producing biofilm.
**No. of strains producing biofilm.
***3GC: third-generation cephalosporins.
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specific biofilm protein [31]. We studied biofilm produc-
tion by H. influenzae stains with the “biofilm ring test”
(Biofilm Control, Saint Beauzire, France) [32]. In the
absence of a standardized method for H. influenzae
(mainly due to the broth medium used and the need for
5% CO2 atmosphere), non-reproducible results were ob-
tained. Therefore, we evaluated biofilm production of
H. influenzae by the modified microtiter plate assay with
CV staining [18]. However, this method still has the draw-
back of possibly removing the established biofilm when
wells are washed. As well, CV as a cationic dye can stain a
biofilm complex structure but also a group of living and
dead bacteria. A limitation of our study is the lack of dir-
ect evaluation of biofilm on biological samples with alter-
native methods such as confocal microscopy after live/
dead staining [33,34]. This method cannot be used with
swabs and cannot be applied retrospectively. Furthermore,
although swabs were in a transport medium, we cannot
exclude that the delay in bacterial culture influenced the
results. Therefore, we used three formulas to calculate
biofilm production, and quantifying bacterial biofilm.
Rayner et al. hypothesized that H. influenzae could
not be isolated from MEF cultures because the biofilm
production disallowed cultivation [34]. AOM bacterial
etiology was suspected because bacterial genetic material
was found by RT-PCR. This hypothesis can explain the
lower rate of biofilm-producing strains in the MEF
group (treatment failure). Indeed, in this group, a double
population may exist and the isolated strain was not the
one producing biofilm; the responsive one may have
been inside a biofilm structure and could not grow on
agar plates.
In another study of 62 children with AOM, 84.3% of
strains produced biofilm [33]. Nevertheless, this study
lacked a control group. Clinical follow-up showed no
significant difference in biofilm production between
strains isolated from children with cured AOM and from
patients with AOM treatment failure after 14 days of
appropriate antibiotic therapy (78.6% vs 90%).
The co-localization of NT-Hi and S. pneumoniae sug-
gests a synergistic interaction between the two organ-
isms. To explain AOM treatment failure in the chinchilla
middle ear, Weimer et al. suggested that H. influenzae
and S. pneumoniae cohabitation may promote biofilm
production of S. pneumoniae [35]. However, Tikhomirova
A. et al. [36] questioned whether the relation between
H. influenzae and S. pneumoniae is competitive or co-
operative. We found no difference in biofilm production
with H.influenzae alone or combined with S. pneumoniae.
Slinger et al. showed that MICs of H. influenzae for
various antibiotics (amoxicillin, amoxicillin/clavulanic
acid, ciprofloxacin) were higher when bacteria are living
in the biofilm than in the planktonic state [37]. As well,
Starner et al. showed that a low concentration of various
antibiotics stimulated biofilm production by H. influenzae
[38]. We determined whether prior administration of anti-
biotics was a risk factor of carrying a biofilm-producing
strain. Indeed, according to the biofilm definition, bacteria
living in an ECM resist the action of antibiotics. Con-
versely, Ehrlich et al. showed that after inoculation of
H. influenzae into the middle ear of chinchillas, strains
produced an ECM whose amount increased with time
[39]. Then, after an administration of antibiotics 96 hr,
bacterial biofilm disappeared, whereas, by definition, it
was expected to be resistant to antibiotics. We found no
significant difference in biofilm production among strains
from children with and without antibiotics treatment
(amoxicillin/clavulanic acid or 3GC) in the previous 3 months.
We did not confirm that prior administration of antibi-
otics affected biofilm production by H. influenzae.
Finally, we observed two kinds of strains: 1) strains
with a high production of biofilm (55.8% to 60.5%)
in NP samples from healthy children and from AOM
children without conjunctivitis and 2) strains with a
lower production of biofilm (40.5% and 31.15%) in MEF
or NP samples from children with AOM and conjunctiv-
itis, respectively.
Recently, Sanchez et al. [40] examined whether S.
pneumoniae in biofilms was virulent and contributed to
invasive pneumococcal disease (IPD) development. The
authors suggested that biofilms did not directly contrib-
ute to development of IPD and may instead confer a
quiescent mode of growth during colonization. They
challenged mice with equal colony-forming units of bio-
film and planktonic pneumococci and determined that
biofilm bacteria production was highly attenuated in in-
vasive disease but not NP colonization.
Finally, we observed two kinds of strains: 1) strains
with a high production of biofilm (55.8% to 60.5%)
in NP samples from healthy children and from AOM
children without conjunctivitis and 2) strains with a
lower production of biofilm (40.5% and 31.15%) in MEF
or NP samples from children with AOM and conjunctiv-
itis, respectively.
Conclusions
This study emphasizes the frequency of biofilm produc-
tion by H. influenzae and also the complexity of the
phenomenon, because 49% of the strains produced bio-
film. We did not find increased biofilm production in
strains isolated from children with AOM treatment fail-
ure or recurrent AOM. H. influenzae involved in the
conjunctivitis-otitis syndrome showed significantly low
biofilm production. We observed the same low produc-
tion in strains with PBP modification, conferring resist-
ance to ampicillin, as compared with susceptible strains.
These observations require study of a larger number
of strains to confirm these results and explore other
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directions. To our knowledge, this is the first study
evaluating the biofilm production by H. influenzae in NP
samples from healthy children. With 49% of the strains
producing biofilm, growing inside a biofilm may consti-
tute a natural mode of growth for the bacteria, especially
in the upper airways of children.
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